Global Xerophthalmia Treatment Market - 2022-2029

Market Overview

The global xerophthalmia treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Xerophthalmia is a medical condition in which the eye fails to produce tears. It could be caused by vitamin A deficiency, which is a term that is sometimes used to describe the condition, but other factors could also cause it.

Market Dynamics

The factors influencing the global xerophthalmia treatment market are the increasing demand for xerophthalmia treatment and the growing prevalence of xerophthalmia.

The increasing demand for xerophthalmia treatment is expected to drive the market growth

Xerophthalmia can affect people of any age group, but it is most common in preschoolers, adolescents, and pregnant women. On the other hand, children are more susceptible to vitamin A deficiency and xerophthalmia due to their higher vitamin A requirements for growth.

Intestinal infestations and infections are also more common in children, impair vitamin A absorption and cause it to be lost.

Vitamin A therapy or supplementation is the most common treatment for xerophthalmia. Vitamin A can be taken orally or administered intravenously. Other medications, such as antibiotics, may be prescribed by the doctor to prevent eye infections. Vitamin A therapy is used to treat xerophthalmia in both adults and children. The dose is determined by the patient's age and the severity of their xerophthalmia. The doctor may also advise the patients to consume plenty of beta-carotene-rich yellow fruits and vegetables. They can also suggest that the patient eat more green leafy vegetables, meat, and dairy. If other factors cause xerophthalmia, the doctor may work with the patient to address the underlying issue.

Limitations associated with xerophthalmia treatment are expected to hamper the market growth

Accurate doses of treatment should be administered in patients suffering from xerophthalmia. If not, it can hamper market growth. For instance, vitamin A (retinol) PO, except in pregnant women, treatment is the same regardless of the clinical stage. The capsules as a whole should not be swallowed. The capsule should be opened and placed directly into the mouth. Vitamin A deficiency in breastfed infants younger than 6 months is uncommon. Moreover, to avoid overdosing, keep track of all doses given on the health/immunization card and do not exceed the recommended doses. Overdosing on vitamin A can result in increased intracranial pressure (bulging fontanelle in infants; headache, nausea, vomiting) and impaired consciousness and convulsions in severe cases. These side effects are temporary, and they require medical monitoring and, if necessary, symptomatic treatment.

COVID-19 Impact Analysis

The covid-19 outbreak has affected many sectors. Especially the economy all over the world.And will also affect the xerophthalmia treatment, market-creating supply chain, and market

disruption, affecting production and demand. Amidst the COVID-19 crisis and social distancing recommendations, general visits to an ophthalmologist have decreased.This might affect the market.A recent study has shown that the number of general medical emergency departments (ED)visits have declined 42% during the early COVID-19 pandemic. Another recent study hasshown that during the national lockdown in Italy, the number of total visits to an eye-specificED in Bologna, Italy, decreased. Hence, the global xerophthalmia treatment market is expected to be impacted.

Segment Analysis

The artificial tears segment is expected to dominate the market growth in the forecast period

Xerophthalmia treatment includes nonprescription eye drops and ointments to relieve the eyes, such as artificial, preservative-free tears, and similar to natural tears. It's important to remember that not all tear products are created equal, and each patient's needs differ slightly. Some of these products are aqueous and provide temporary relief from symptoms.

Preservative-free artificial tears are more frequently recommended because they provide more relief and do not irritate the eyes. Avoid products that claim to remove redness or "whiten" the eyes because they lack the necessary moisturizing properties and often exacerbate the problem. In more serious cases, an ophthalmologist may place special caps in the lacrimal punctum to keep natural and artificial tears from draining out (with either temporary collagen caps that will be absorbed or permanent silicone caps). People with xerophthalmia should avoid dust, pollen, smoking, and other polluting factors in the environment. Furthermore, their prolonged exposure to extreme heat will exacerbate xerophthalmia. On the other hand, interior moisturizers can help because they add moisture to the skin, which helps to prevent tear evaporation.

Geographical Analysis

Asia Pacific region is expected to hold the largest market share in the global xerophthalmia treatment market

The growing prevalence of xerophthalmia and increasing micronutrient deficiency are expected to drive this region's market growth. According to estimates, 1.02 billion people worldwide are severely deficient in micronutrients, with vitamin A being the most deficient nutrient in the body. According to similar studies, India is home to 85 percent of all South Asian children with xerophthalmia. In developing countries, vitamin A deficiency is a major, preventable nutritional issue. Vitamin A deficiency is thought to be responsible for the blindness of 30-40,000 children in India. Among South Asian countries, India has the highest prevalence of clinical and subclinical VAD, with 62 percent of preschool children being vitamin A deficient. These startling findings pointed to a high mortality rate, with 330,000 children dying each year. According to estimates, subclinical VAD affects 31 percent to 57 percent of preschool children.

Competitive Landscape

The global xerophthalmia treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Allergan Plc, Akorn, Inc, Thea Pharmaceuticals Limited, OASIS Medical, Scope Ophthalmics Ltd., Medicom Healthcare Ltd, FDC Limited, Jamjoom Pharmaceuticals Co., Sentiss Pharma Private Limited, Johnson & Johnson Inc.

Allergan Plc

Overview: Allergan plc is an American pharmaceutical company headquartered in Dublin, Ireland. It acquires, develops, manufactures, and markets brand-name drugs and medical devices in medical aesthetics, eye are, central nervous system, and gastroenterology. The company was founded in 2013.

Product Portfolio: The ophthalmic emulsions RESTASIS and RESTASIS MultiDose(cyclosporine ophthalmic emulsion) help increase the eyes' natural ability to produce tears, which inflammation caused by chronic dry eye.

Why Purchase the Report?

Visualize the composition of the global xerophthalmia treatment market segmentation by type and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in global xerophthalmia treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global xerophthalmia treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global xerophthalmia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers